Virafin for moderate Covid 19

April 26, 2021

The Drugs Controller General of India (DGCI) on Friday approved the emergency use for Zydus Cadila’s Pegylated Interferon alpha-2b ‘Virafin’ for treating moderate COVID-19 infection for adults. Zydus Cadila announced that it has received emergency use approval from DCGI to use Virafin for the treatment of moderate COVID-19 infections. As per the report, a single-dose subcutaneous regimen of the drug will make the treatment of COVID-19 more convenient. The company had said that if administered early on during COVID-19, Virafin may help patients recover faster and avoid much of the complications. It will be available on the prescription of a medical specialist.

Virafin for moderate Covid 19

RELATED NEWS

Supreme Court hearing on Anti-Corruption Amendment Bill adjourned until Friday

Police officers warned over refusal to accept digital insurance cards

10 injured after wild elephant attacks bus on Kataragama-Buttala road

Sri Lanka sets mandatory qualifications for solar technicians from 2028

Supreme Court hearing on Anti-Corruption Amendment Bill adjourned until Friday

Police officers warned over refusal to accept digital insurance cards

10 injured after wild elephant attacks bus on Kataragama-Buttala road

Sri Lanka sets mandatory qualifications for solar technicians from 2028

Supreme Court begins hearing petitions against Anti-Corruption Amendment Bill

Supreme Court begins hearing petitions against Anti-Corruption Amendment Bill

Sri Lanka opens Mannar Basin exploration to companies from India, China and elsewhere

Sri Lanka monitoring 11 Iranian vessels south of Galle: foreign minister

Sri Lanka calls for fairer global financial system, stronger voice for developing countries